NASDAQ:CBAYCymaBay Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CymaBay Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.55 +0.05 (+1.43 %) (As of 07/31/2020 04:00 PM ET) Add Compare Share Today's Range$3.47Now: $3.55▼$3.8750-Day Range$3.32MA: $3.69▼$4.3952-Week Range$1.21Now: $3.55▼$6.56Volume4.63 million shsAverage Volume3.72 million shsMarket Capitalization$244.52 millionP/E RatioN/ADividend YieldN/ABeta1.38 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, CymaBay Therapeutics has a potential upside of 181.7% from its current price of $3.55.Amount of Analyst CoverageCymaBay Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesCymaBay Therapeutics has received 439 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCymaBay Therapeutics has received 305 “underperform” votes. (Add your “underperform” vote.)Community SentimentCymaBay Therapeutics has received 59.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote “Outperform” if you believe CBAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions85.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($0.93) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY Previous Symbol CUSIPN/A CIK1042074 Webwww.cymabay.com Phone510-293-8800Debt Debt-to-Equity Ratio0.01 Current Ratio15.60 Quick Ratio15.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10 million Price / Sales24.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book1.31Profitability EPS (Most Recent Fiscal Year)($1.46) Net Income$-102,810,000.00 Net MarginsN/A Return on Equity-43.33% Return on Assets-39.90%Miscellaneous Employees43 Outstanding Shares68,880,000Market Cap$244.52 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable $3.55 +0.05 (+1.43 %) (As of 07/31/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CBAY News and Ratings via Email Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter. CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions How has CymaBay Therapeutics' stock been impacted by COVID-19 (Coronavirus)? CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CBAY stock has increased by 130.5% and is now trading at $3.55. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CymaBay Therapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CymaBay Therapeutics. When is CymaBay Therapeutics' next earnings date? CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for CymaBay Therapeutics. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.12. View CymaBay Therapeutics' earnings history. What price target have analysts set for CBAY? 12 Wall Street analysts have issued twelve-month price targets for CymaBay Therapeutics' stock. Their forecasts range from $6.00 to $15.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 181.7% from the stock's current price. View analysts' price targets for CymaBay Therapeutics. Has CymaBay Therapeutics been receiving favorable news coverage? News articles about CBAY stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CymaBay Therapeutics earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about CymaBay Therapeutics. Are investors shorting CymaBay Therapeutics? CymaBay Therapeutics saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 8,110,000 shares, a decrease of 8.7% from the June 15th total of 8,880,000 shares. Based on an average trading volume of 3,320,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 12.3% of the company's stock are sold short. View CymaBay Therapeutics' Current Options Chain. Who are some of CymaBay Therapeutics' key competitors? Some companies that are related to CymaBay Therapeutics include Phathom Pharmaceuticals (PHAT), VBI Vaccines (VBIV), Phibro Animal Health (PAHC), DiaMedica Therapeutics (DMCAF), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), BioXcel Therapeutics (BTAI), Arcus Biosciences (RCUS), Generation Bio (GBIO), Athenex (ATNX), Aimmune Therapeutics (AIMT), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Stoke Therapeutics (STOK) and Repare Therapeutics (RPTX). View all competitors. What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Energy Transfer LP Unit (ET), Alibaba Group (BABA), TG Therapeutics (TGTX), Opko Health (OPK), Exelixis (EXEL), AT&T (T), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Advanced Micro Devices (AMD) and Roku (ROKU). Who are CymaBay Therapeutics' key executives? CymaBay Therapeutics' management team includes the following people: Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)Mr. Daniel Menold, VP of Fin. (Age 49)Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)Dr. Pol F. Boudes, Chief Medical Officer (Age 62) What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include UBS Group AG (0.55%) and SG Americas Securities LLC (0.06%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah. View institutional ownership trends for CymaBay Therapeutics. Which institutional investors are buying CymaBay Therapeutics stock? CBAY stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, and UBS Group AG. View insider buying and selling activity for CymaBay Therapeutics. How do I buy shares of CymaBay Therapeutics? Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $3.55. How big of a company is CymaBay Therapeutics? CymaBay Therapeutics has a market capitalization of $244.52 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-102,810,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe. What is CymaBay Therapeutics' official website? The official website for CymaBay Therapeutics is www.cymabay.com. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
